Advanced Biomed is trading 6.76% up at $9.16, extending its volatile recent advance; no reliable August 14 company-specific announcement was found to explain the move.
- It closed at $8.58 on August 13, 2026.
- The frequently referenced 120-case A+PerfusC feasibility study was announced on February 13, 2026, making it stale rather than a new catalyst.
- Broader markets are slightly weaker, so macro sentiment does not clearly explain the gain.